A new PARTNER 2 analysis suggests a lack of short-term impact of early anticoagulation on hemodynamics and most clinical outcomes regardless of whether replacement was percutaneous or surgical. But definitive guidance awaits randomized investigation.
Two trials comparing transcatheter (TAVR) with surgical aortic valve replacement in patients at low surgical risk found TAVR to yield equal or better outcomes. While a new indication seems certain, some key questions remain.
Heterogeneity is the rule with bicuspid aortic valves, so optimal surgical solutions vary by patient. Our experts share experience-based guidance for managing various presentations of BAV and aortopathy.
The most comprehensive literature review of structural valve deterioration to date just took on this question. Although data were abundant, useful comparisons were few. The authors explain.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Our experts outline their vision of ideal changes to the National Coverage Determination for programs performing transcatheter aortic valve replacement. A CMS decision is due in June 2019.
The latest PARTNER 2A analysis finds that worsening RV function is much more common after SAVR than TAVR. And it predicts greater risk for poor outcomes regardless of procedure type.
The Inspiris Resilia aortic bioprosthesis is officially launched, and Cleveland Clinic just performed some of its first U.S. commercial implantations. A COMMENCE trial investigator reflects on the device’s points of distinction.
Long-term survival after surgical aortic valve replacement is lower when it’s for aortic stenosis that’s due to prior chest radiotherapy, a new study shows. But it’s too soon to assume TAVR is a panacea.
The newly approved Inspiris Resilia valve broadens options for aortic valve replacement patients in whom durability is a priority. Plus it’s designed to ease eventual valve-in-valve procedures, if needed.
In this Q&A, Cleveland Clinic experts explore how to weigh patient age when deciding between surgical and transcathether AVR and what matters most to procedure choice for treating a degenerated aortic bioprosthesis.